<table>
<thead>
<tr>
<th>Clinical Setting</th>
<th>Therapy</th>
<th>Duration</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invasive Aspergillosis (IA)</td>
<td><strong>Infectious Disease Consult is STRONGLY recommended if Aspergillosis is</strong></td>
<td>Minimum of 3-6 months; determined by clinical response, &amp; radiological response, &amp; patient’s underlying disease or immune status.</td>
<td>See Page 2 for Dosing, Therapeutic Drug Monitoring, Drug-Drug Interactions, Adverse Reactions, Breakthrough Infection/Salvage Therapy, and Miscellaneous information for Aspergillosis Treatment</td>
</tr>
<tr>
<td><strong>Categories (see footnote for host and radiology criteria):</strong></td>
<td><strong>Proven IA:</strong> histopathology demonstrating invasive disease or culture of a sterile site</td>
<td><strong>Preferred</strong> (all three are therapeutically equivalent)(^4,5), choice dependent on drug interaction and toxicity considerations, as well as insurance coverage):</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Isavuconazole</strong> 372 mg q8h PO/IV x48 hours, then 372 mg PO/IV daily. Capsules may be opened and administered through feeding tube.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>OR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Posaconazole</strong> 300 mg (PO/IV) BID on Day 1 then 300 mg PO daily starting on Day 2. Tablets may be crushed and administered through feeding tube.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>OR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Voriconazole</strong> 6 mg/kg PO/IV q12h x2 doses, then 4 mg/kg PO/IV q12h (on an empty stomach).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>OR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>May Consider</strong> initial combination therapy (Mycafungin 150 mg IV daily x2 weeks PLUS voriconazole, posaconazole, or isavuconazole) in patients with PROVEN or PROBABLE disease who meet ANY of the following:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Have extensive multi-lobar involvement or disseminated infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Have increasing oxygen requirements or respiratory distress with impending respiratory failure.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Expected long duration of neutropenia (&gt;10 days) or extensive GVHD.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Alternative in patients intolerant to above azole agents or with refractory or breakthrough disease, or unable to receive azoles due to interaction:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>LAmB (liposomal amphotericin B)</strong> 3-5 mg/kg IV daily</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Invasive Aspergillosis Comments

Dosing
- Dosing guidelines available [here](#).
- Weight-based dosing recommendations for adult obese patients available [here](#).
- Loading doses are necessary to achieve more rapid attainment of therapeutic levels. As such, when switching from oneazole to another, loading doses are recommended.

Therapeutic drug monitoring
- Therapeutic drug monitoring is recommended for isavuconazole, posaconazole, and voriconazole. Please see Recommendations for Therapeutic Drug Monitoring of Antifungal Agents [here](#).

Drug Interactions
- Numerous significant drug interactions occur with azole antifungals. A review of the patient profile should be undertaken when these agents are initiated and discontinued (see footnote for specific notes).

Adverse Reactions
- Posaconazole and voriconazole have been associated with QTc prolongation. Isavuconazole is associated with dose-dependent decreases in QTc interval. As such, isavuconazole may be preferred in some patients experiencing issues with QTc prolongation (>500 msec).
- Patients with a prolonged QTc or on select anti-arrhythmics such as dofetilide or sotalol should avoid voriconazole/posaconazole or perform EKG monitoring due to an increase risk of QT-prolongation and torsades.
- Unlike posaconazole and voriconazole, isavuconazole is water-soluble and thus does not require solubilization by cyclodextrin for an intravenous formulation. There are potential nephrotoxicity concerns with cyclodextrin in patients with pre-existing renal impairment. However, there is no strong clinical evidence suggesting an increased risk of worsening renal function with IV voriconazole use, and so the benefit of using intravenous posaconazole or voriconazole outweigh any theoretical nephrotoxicity risks.
- Isavuconazole and posaconazole are associated with significantly less visual disturbances, hallucinations, and photosensitivity compared to voriconazole. Of note, visual hallucinations with voriconazole are usually transient (associated with loading dose) and/or associated with supra-therapeutic levels (>5.5 ug/mL). Visual disturbances, such as photopsia, are not dose dependent, may continue to occur, but have no long-term consequences.
- Isavuconazole was associated with fewer hepatobiliary adverse effects than voriconazole (9% vs. 16%, respectively) in a trial of aspergillosis. However, hepatic adverse effects with voriconazole are generally both reversible and do not require discontinuation in clinical trials. As such, pre-existing hepatic impairment is not a contraindication to voriconazole and mild elevations during therapy are often multi-factorial and do not necessarily mandate a change in therapy. Patients with cirrhosis may have supratherapeutic levels on standard dosages of voriconazole. As such, therapeutic drug monitoring recommendations should be followed and ID Pharmacy (pager 31888) should be contacted for dosing recommendations in patients with cirrhosis.

Breakthrough Infection and Salvage Treatment
- Patients with breakthrough infection on voriconazole/isavuconazole/posaconazole prophylaxis may be at risk for azole resistance. If an isolate is available, susceptibilities should be performed.
- Current and prior azole concentrations during prophylaxis/treatment should be reviewed when assessing breakthrough infection or need for salvage therapy.
- Converting to LAmB is recommended. In select cases, changing to an alternative azole may be appropriate.

Miscellaneous
- Investigational agents may be available for patients intolerant/resistant/refractory to other therapies. Contact Infectious Diseases and/or Antimicrobial Stewardship to discuss.
- In patients with central nervous system and/or ocular involvement, voriconazole therapy is preferred. Liposomal Amphotericin B therapy is appropriate for patients intolerant or refractory to voriconazole. There is insufficient data regarding preference of other alternatives, and such decisions should be made on a case-by-case basis.
- In patients with endophthalmitis, voriconazole (concomitant systemic and intravitreal) therapy is preferred.
<table>
<thead>
<tr>
<th>Clinical Setting</th>
<th>Therapy</th>
<th>Duration</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Proven or Probable Mucormycosis (e.g., Rhizopus spp., Mucor spp., Rhizomucor spp., others) | Infectious Disease Consult is STRONGLY recommended if Mucormycosis is suspected | Generally prolonged (months). Until resolution of clinical signs and symptoms or treatment limiting adverse effects | • Please note that voriconazole IS NOT ACTIVE against mucormycosis  
• See above (Invasive Aspergillosis) section for dosing recommendations. Complete dosing guidelines available here  
• Weight-based dosing recommendations for adult obese patients available here  
• Therapeutic drug monitoring is recommended for isavuconazole and posaconazole. Please see Recommendations for Therapeutic Drug Monitoring of Antifungal Agents here  
• Investigational agents may be available for patients intolerant/resistant/refractory to other therapies. Contact Infectious Diseases and/or Antimicrobial Stewardship to discuss. |
| | Primary Surgical debridement is generally necessary | |  |
| | LAmB 5 mg/kg IV daily with consideration of escalation to a maximum of 10 mg/kg daily in patients with progressive or extensive disease or possible CNS disease | |  |
| | Combination therapy should be discussed with ID Consultant  
Options for step-down therapy, salvage therapy, or in patients unable to take LAmB include isavuconazole or posaconazole. Consultation with ID is highly recommended | |  |

Specific Recommendations Regarding Drug Interactions with Azoles:

- Isavuconazole, Posaconazole, and voriconazole all inhibit CYP3A4, although isavuconazole is a more mild inhibitor than the other two agents. Voriconazole uniquely also inhibits CYP 2C9/2C19.
- P-450 inducers (e.g., rifampin, phenobarbital, carbamazepine, St. John’s wort) may result in subtherapeuticazole levels
- Sirolimus, tacrolimus, and cyclosporine levels increase. Drug levels and dose adjustment may be necessary in consultation with transplant pharmacy
- Concomitant use of azoles in hematology/oncology patients on chemotherapeutic agents or targeted therapies should be discussed with hematology
- Complex drug interactions with antiretroviral agents exist and may alter serum azole and/or antiretroviral levels

Host and Radiologic Criteria for the Diagnosis of Invasive Fungal Infection

- Host factors:
  - Recent history of neutropenia (< 500 neutrophils/mm³ for > 10 days) temporally related to the onset of fungal disease
  - Hematologic malignancy
  - Receipt of an allogeneic stem cell transplant
  - Prolonged use of corticosteroids (excluding among patients with allergic bronchopulmonary aspergillosis) at a mean minimum dose of 0.3 mg/kg/day of prednisone equivalent for > 3 weeks in past 60 days
  - Treatment with other recognized T cell immunosuppressants, such as calcineurin inhibitors, TNF-a blockers, lymphocyte-specific monoclonal antibodies (such as alemtuzumab), or immunosuppressive nucleoside analogues during the past 90 days

---

**Page 3 of 4**
- Treatment with recognized B-cell immunosuppressants, such as Bruton’s tyrosine kinase inhibitors, e.g., ibrutinib
- Inherited severe immunodeficiency (such as chronic granulomatous disease or severe combined immunodeficiency)
- Acute graft-versus-host disease grade III or IV involving the gut, lungs, or liver that is refractory to first-line treatment with steroids

Suggestive radiologic/clinical findings:
- Lower respiratory tract fungal disease
  - The presence of 1 of the following 4 patterns on CT:
    - Dense, well-circumscribed lesions(s) with or without a halo sign
    - Air-crescent sign
    - Cavity
    - Wedge-shaped and segmental or lobar consolidation

References: